Abstract:The aminocoumarin antibiotics novobiocin, clorobiocin and coumermycin A1 are produced by different Streptomyces strains. They are potent inhibitors of bacterial gyrase and topoisomerase IV, and novobiocin has been licensed as antibiotic for clinical use (Albamycin®). They also have potential applications in oncology. The biosynthetic gene clusters of all three antibiotics have been cloned and sequenced, and the function of nearly all genes contained therein has been elucidated. Rapid and versatile methods have been developed for the heterologous expression of these biosynthetic gene clusters, and in Streptomyces coelicolor M512 as heterologous host these antibiotics were produced in yields comparable to those in the natural producer strains. λ RED-mediated homologous recombination was used for genetic modification of the gene clusters in Escherichia coli. The phage φC31 attachment site and integrase functions were introduced into the cosmid backbones and employed for stable integration of the clusters into the genome of the heterologous hosts. Modification of the clusters by single or multiple gene replacements or gene deletions resulted in the formation of numerous new aminocoumarin derivatives, providing an efficient tool for the rational generation of antibiotics with modified structure. Additionally, many new antibiotics were generated by mutasynthesis experiments, i.e. the targeted deletion of genes required for the biosynthesis of a certain structural moiety of the antibiotic, and the replacement of this moiety by structural analogs which were added to the culture broth. The diversity of new structures obtained by this approach could be expanded by further genetic modifications of the gene deletion mutants, especially by expression of heterologous biosynthetic enzymes with appropriate substrate specificity. Keywords: acyl carrier protein, Novobiocin, clorobiocin analogs, genetic manipulations, Streptomyces coelicolor

New aminocoumarin antibiotics as gyrase inhibitors.

New Aminocoumarin Antibiotics from Genetically Engineered Streptomyces Strains.

Biological Activities of Novel Gyrase Inhibitors of the Aminocoumarin Class

In Vitro and in Vivo Production of New Aminocoumarins by A Combined Biochemical, Genetic, and Synthetic Approach

Functional Analysis of Biosynthetic Genes of Aminocoumarins and Production of Hybrid Antibiotics

Unique Aminothiazolyl Coumarins As Potential DNA and Membrane Disruptors Towards Enterococcus Faecalis

Inhibition of DNA Gyrase and DNA Topoisomerase IV of Staphylococcus Aureus and Escherichia Coli by Aminocoumarin Antibiotics.

Structure-activity relationships of aminocoumarin-type gyrase and topoisomerase IV inhibitors obtained by combinatorial biosynthesis.

Chapter 18 Aminocoumarins

Genetic Engineering of Antibiotic Biosynthesis for the Generation of New Aminocoumarins

Novel Aminopyrimidinyl Benzimidazoles As Potentially Antimicrobial Agents: Design, Synthesis and Biological Evaluation

Metabolic Engineering of Aminocoumarins: Inactivation of the Methyltransferase Gene Clop and Generation of New Clorobiocin Derivatives in a Heterologous Host

Discovery of 2-Aminothiazolyl Berberine Derivatives As Effectively Antibacterial Agents Toward Clinically Drug-Resistant Gram-negative Acinetobacter Baumanii.

Aminocoumarins: Mutasynthesis, Chemoenzymatic Synthesis, And Metabolic Engineering

Combinatorial Biosynthesis, Metabolic Engineering and Mutasynthesis for the Generation of New Aminocoumarin Antibiotics

Antimicrobial and DNA Gyrase-Inhibitory Activities of Novel Clorobiocin Derivatives Produced by Mutasynthesis.

New Aminocoumarin Antibiotics Derived from 4-Hydroxycinnamic Acid Are Formed after Heterologous Expression of a Modified Clorobiocin Biosynthetic Gene Cluster

Discovery of N-quinazolinone-4-hydroxy-2-quinolone-3-carboxamides As DNA Gyrase B-targeted Antibacterial Agents

Simocyclinone D8, an Inhibitor of Dna Gyrase with A Novel Mode of Action

Novel Bacterial Topoisomerase Inhibitors with Potent Broad-Spectrum Activity against Drug-Resistant Bacteria

Optimized Arylomycins Are a New Class of Gram-negative Antibiotics.